Entering text into the input field will update the search result below

Sangamo Therapeutics begun at neutral at Wedbush on 'frontrunner' Fabry candidate

Detail of Wall Street Sign

narvikk/E+ via Getty Images

Wedbush Securities has initiated Sangamo Therapeutics (NASDAQ:SGMO) with a hold rating noting that while it sees promise in isaralgagene civaparvovec for Fabry disease, the candidate needs to demonstrate better durable efficacy and safety compared to

Recommended For You

About SGMO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SGMO--
Sangamo Therapeutics, Inc.